RecruitingNCT06775470

Impact of Different BRCA1/2 Gene Variants on Response to Therapy and Prognosis of Ovarian Cancer

Impatto Delle Diverse Varianti Dei Geni BRCA1/2 su Risposta Alla Terapia e Prognosi Del Carcinoma Ovarico

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

300 participants

Start Date

Jul 1, 2022

Study Type

OBSERVATIONAL

Conditions

Ovarian Cancer

Summary

Identify any significant differences in terms of drug response and survival between the different possible alterations in the BRCA1/2 genes, in order to stratify ovarian cancer patients with a view to increasingly personalised and thus effective therapy.

Eligibility

Sex: FEMALE

Inclusion Criteria3

ovarian cancer diagnosis by 31/12/2021;
BRCA test at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S.Orsola by 31/12/2021;
follow-up and/or treatment at Medical Oncology and/or Gynaecological Oncology of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months

Exclusion Criteria1

ovarian carcinoma of 'mucinous' or 'borderline' histotype.

Interventions

DIAGNOSTIC_TESTPatients must have been diagnosed with ovarian cancer and be BRCA positive

Patients must have been diagnosed with ovarian carcinoma by 31/12/2021, have undergone BRCA testing at the UOC of Medical Genetics of the IRCCS AOU of Bologna Policlinico S. Orsola by 31/12/2021 and have been taken on for follow-up and/or treatment at the Medical Oncology - Zamagni and/or Gynaecological Oncology - De Iaco of the IRCCS Azienda Ospedaliero-Universitaria (AOU) of Bologna for a period of time of at least 1 year and by 31/12/2021 and for a minimum period of 6 months.

DIAGNOSTIC_TESTBRCA1 and BRCA2 positive, and be affected by Ovarian Cancer